Division of Internal Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Am J Cardiol. 2019 Dec 1;124(11):1785-1789. doi: 10.1016/j.amjcard.2019.08.040. Epub 2019 Sep 9.
Aspirin use in the prevention of cardiovascular events has been a mainstay of treatment for decades. However, the use of aspirin in primary prevention of atherosclerotic cardiovascular disease has recently come under scrutiny. Several recent studies have evaluated the use of aspirin in primary prevention and the results suggest that in many patients the risks may outweigh the benefits. Closer examination of these trials suggests that the use of aspirin therapy for primary prevention may have a role but likely needs a more tailored approach and that caution is needed in prescribing aspirin for primary prevention. In conclusion, in this article we review the evolving evidence for aspirin in the primary prevention of atherosclerotic cardiovascular disease.
阿司匹林用于预防心血管事件已成为数十年来的主要治疗方法。然而,阿司匹林在动脉粥样硬化性心血管疾病一级预防中的应用最近受到了质疑。最近的几项研究评估了阿司匹林在一级预防中的应用,结果表明,在许多患者中,风险可能大于获益。对这些试验的更仔细检查表明,阿司匹林治疗在一级预防中可能有一定作用,但可能需要更有针对性的方法,在开阿司匹林用于一级预防时需要谨慎。总之,本文回顾了阿司匹林在动脉粥样硬化性心血管疾病一级预防中的不断发展的证据。